JNJ Shares Rise as Litigation Cloud Lifts and Sales Growth Firms Up

Johnson & Johnson (NYSE:JNJ) shares have been on the rise after the company made significant progress in resolving its long-standing talc-related litigation. The healthcare giant's quarterly sales growth has also firmed up, with a full-year view that has moved higher.

The company operates across two main pillars: pharmaceuticals and medical technology. Its pharmaceutical business develops prescription medicines for various therapeutic areas, while its medical technology arm supplies devices and equipment used in surgery, cardiovascular care, and other fields.

Johnson & Johnson's recent quarterly results showed an increase in net sales, with the company raising its full-year view. The strength in the results was attributed to both the pharmaceutical and medical technology arms, with established medicines expanding and newer therapies contributing to growth.